PI-88 News
Most Popular PI-88 Story
Progen lung cancer therapy flunks Phase II
Progen Pharmaceuticals disappointed its investors with news this morning that its experimental therapy, PI-88, failed a mid-stage trial for lung cancer. The trial, which combined the experimental... Read more...
Latest Headlines
- July 24, 2008
- September 24, 2007
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
